Rapamycin (Sirolimus) 化学構造
分子量: 914.18

高品質保証

文献中の引用(63)

カスタマーフィードバック(12)

MSDS

製品説明

  • Compare mTOR Inhibitors
    mTOR製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Rapamycin (Sirolimus)は一種の特定なmTOR 阻害剤で、HEK293細胞中でIC50 値が約0.1 nMです。
ターゲット

mTOR

IC50

~0.1 nM [1]

In vitro試験 Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29 NYS0NIVVS3m2b4TvfIlkKEG|c3H5 M1rRTVExKG6P Ml7IO|IhcA>? MVvEUXNQ NIjW[3JRd3SnboTpZZRmeyClYX3weI91cGWlaX6tbY5lfWOnZDDjfZRwfG:6aXPpeJk> MmfUNlQ6ODB6N{O=
HT-29 NVrCWHFuS3m2b4TvfIlkKEG|c3H5 Ml7lNVAhdk1? M2XHfFczKGh? M3zqN2ROW09? MX\Qc5RmdnSrYYTld{BlcWerdH;4bY4ucW6mdXPl[EBkgXSxdH;4bYNqfHl? M2rZ[|I1QTByOEez
HT-29 NY\R[FQ6S3m2b4TvfIlkKEG|c3H5 NGqwOVYyOCCwTR?= NFi4OHc4OiCq NWTwZ|h7TE2VTx?= M3PWS3BwfGWwdHnheIV{KDVvZnz1c5JwfXKjY3nsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 MkS0NlQ6ODB6N{O=
PC3 NX3UTFcxU2mwYYPlJGF{e2G7 M3TldlExOCCwTR?= MVmxJIg> MWjEUXNQ NH22PIxRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhRDFyIH7NMi=> NFjifpczOTl5OE[4Ny=>
PC3 Ml;uT4lv[XOnIFHzd4F6 NHjzZnUyODBibl2= MU[xJIg> NXfoWlR2TE2VTx?= M3fsfWRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w NYTYd3V1OjF7N{i2PFM>
PC3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYKxMlUh|ryP NYnEWYdjOSCq NYPMTnNbTE2VTx?= NFP3T3NKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy|IIfpeIghUUN3MDDv[kA9OTBibl2= NV\xUopsOjF7N{i2PFM>
HEK293 M2nBOWZ2dmO2aX;uJGF{e2G7 NXrqSG9iOTByIH7N MV[4JIg> NUDwOYRlTE2VTx?= NV\weGh7UW6qaXLpeJMhXFCDLXnu[JVk\WRiZHXndoFl[XSrb36gc4YhWGSlZESge4l1cCCHQ{WwJI9nKDVyIH7N MVyyNVU{QTNyMR?=
BT-20 MmD2T4lv[XOnIFHzd4F6 NFHGbYYzOCEQvF2= MWrEUXNQ NEiwSIhFd2W|IH7veEBqdmirYnn0JI1VV1KFMjDk[ZBmdmSnboSgdGFsXCCVNEezJJBpd3OyaH;yfYxifGmxbh?= MkmzNlE{PTN3NUG=
U937 M4W1T2FvfGmkYXP0[ZJq[WxiQYPzZZk> NHXXWJY2OCEQvF2= NHnNRXc1QCCq M3\FNWROW09? MVXJcoR2[2W|IHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhVGWpaX;u[Yxt[SCybnX1cY9xcGmuYTDQbIlt[WSnbIDobYEuOSCMUkOyJIlvKFV7M{egZ4VtdHN? NFTxTG0zOTF2MkGwOi=>
U937 NUjlO2J3SW62aXLhZ5RmemmjbDDBd5NigQ>? NI\pSlY2OCEQvF2= NX7TSHZFPDhiaB?= NIHRV3BFVVOR MVnEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JG1KWCCycn;0[YlvNWSnZnnjbYVvfCCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJGpTOzJvMjDpckBWQTN5IHPlcIx{ NUS2[Gd1OjFzNEKxNFY>
U937 MWrBcpRq[mGldHXybYFtKEG|c3H5 NF;rTXM2OCEQvF2= NHTrNoQ1QCCq MXLEUXNQ M{PDUWRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhTXOlaHXybYNpcWFiY3;sbUBJSjFyMTDpckBWQTN5IHPlcIx{ MWWyNVE1OjFyNh?=
MCF-7 Ml62RZV1d3CqYXf5JGF{e2G7 MYezNEBvVQ>? MUS0JIg> MV7EUXNQ NHL4XnlKdmS3Y3XzJIF2fG:yaHHnfS=> M2XPbFIxODJ6MUO0
U87MG NIe3N4RMcW6jc3WgRZN{[Xl? MXWxJO69VQ>? NGP4RWU3KGh? NFfHPJpFVVOR MoLRVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25? MUOxPVg1QDRyNB?=
U87MG NHvJd4lMcW6jc3WgRZN{[Xl? NUS4b4xiOSEQvF2= NGjYNGk3KGh? MXHEUXNQ MYLQc5RmdnSueTDpcohq[mm2czC0SWJROSiWN{CpJJBpd3OyaH;yfYxifGmxbh?= MXexPVg1QDRyNB?=
U87MG NUS0WodiU2mwYYPlJGF{e2G7 MlTUNUDPxE1? NVW2dHRjPiCq NF:0S|JFVVOR MonOSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? Ml;XNVk5PDh2MES=
U87MG M3;sbmtqdmG|ZTDBd5NigQ>? NGfqN3kyKM7:TR?= NG\3bpY3KGh? NEPDfG1FVVOR MofrSI9meyCwb4SgbY5pcWKrdDDQMVRGSlBzKGSzO{81PilicHjvd5Bpd3K7bHH0bY9v Ml3GNVk5PDh2MES=
COS7 cells expressing EGFP-HDQ74/rheb Mom2RZV1d3CqYXf5JGF{e2G7 M2jie|AvOiEQvF2= NXz0RpJzOjRiaB?= M3mzZmROW09? MlmzTY5lfWOnczDheZRweGijZ4m= NHP0c4MyQDN7MUm0PS=>
COS7 cells expressing EGFP-LC3 NYP0SVlQSXW2b4DoZYd6KEG|c3H5 NVfudm45OC5{IN88US=> M4PwcVI1KGh? NX70UpB7TE2VTx?= NFXUUJJKdmS3Y3XzJIF2fG:yaHHnfS=> NWK1SGpKOTh|OUG5OFk>
H4 MkT3SpVv[3Srb36gRZN{[Xl? NFXsW2gxNjJizszN MXWyOEBp NHG0e4xFVVOR MnPSTY5kemWjc3XzJJRp\SC{YYTpc{Bw\iCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNkB1dyCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNUBqdiCqdX3hckBJPCClZXzsdy=> NGjRPYYyQDB{NEW4OC=>
HeLa NVP4ZVZOTnWwY4Tpc44hSXO|YYm= M4nUNFExOCCwTR?= MojFN|YhcA>? MVLEUXNQ NH3TUZlKdmS3Y3XzJGZTSiCNMkC5OXAtKFR{MEm4UEwhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v M4mwNlE4PTZ|M{i1
HeLa MX;GeY5kfGmxbjDBd5NigQ>? NWrxRVkxOTByIH7N MlS0N|YhcA>? MkLySG1UVw>? MVTJcoR2[2W|IF\SRkBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> NYfPPGhpOTd3NkOzPFU>
HeLa MUXGeY5kfGmxbjDBd5NigQ>? NFnsb4syODBibl2= MYezOkBp M4DBOmROW09? NGriNIdKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> M1\CUFE4PTZ|M{i1
SYF M2S1ZmZ2dmO2aX;uJGF{e2G7 NWHDTIJ3OTByIH7N NE\hVJQzPCCq NF7XenpFVVOR M13Ee2lv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=> NInueosyPzV4M{O4OS=>
SYF NGraWWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUWxNFAhdk1? M{HxN|I1KGh? NGXPbZdFVVOR MWPJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiU2nGJINmdGy| NUjhSXhCOTd3NkOzPFU>
HEK293T MojWRY51cX[rcnHsJGF{e2G7 M{PtV|Ehdk1? M3\Bb|Qh\A>? M2fMbGROW09? M3zrSWlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCUNTD3bZRpKEWFNUCgc4YhOC5zIH7N MXixO|Q5PTVyMR?=
HEK293T NWnSOXlJSW62aY\pdoFtKEG|c3H5 NFrQ[5AyKG6P M1T3bFQh\A>? M4DTPGROW09? NHLJdJZKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiWESge4l1cCCHQ{WwJI9nKDBwMzDuUS=> MYmxO|Q5PTVyMR?=
PBMC NIfoR3hHfW6ldHnvckBCe3OjeR?= NGTuPWYyKG6P M4fWUlE1KGR? M1jzT2ROW09? M370RXJm\HWlZYOgR2NTPSCmZX7zbZR6 NEOwXXAyPzR6NUWwNS=>
PBMC NGixRYlHfW6ldHnvckBCe3OjeR?= MlTLNUBvVQ>? MV[xOEBl MlnqSG1UVw>? Mn[xSI9meyCwb4SgZYZn\WO2IFPYR3I1KGSnboPpeJk> MkTVNVc1QDV3MEG=
HEK293 cells NHrvRVJMcW6jc3WgRZN{[Xl? MX21NEBvVQ>? M4PDXlQ2KG2rbh?= M3raXGROW09? MV3Jcohq[mm2czDtWG9TKGurbnHz[UBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xJI5O MmXqNVc{PTB7NUO=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MVrGeY5kfGmxbjDBd5NigQ>? M{[wdVExOCCwTR?= NX3yXXVDPCCq NGe5SoNFVVOR M2DnWmlv\HWlZYOgcJVkcW[ncnHz[UBxem:2ZXnuJJRz[W6|LYPwcIlkcW6pIHnuJGRzd3OxcHjpcIEhdWWuYX7v[4F{fGW{IGOyJINmdGy|IITyZY5{\mWldHXkJJdqfGhiTj3seYMh[W6mIFOtcJVk NWDpT3h1OTdzMkiyOlI>
Human mixed lymphocyte NWLGV3hKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjOcpU2KG6P NWDYdGNUTE2VTx?= MkSxTWM2OD1zLk[gcm0v M3TjWFE3OTh3OE[1
Lewis rat lymph node cells MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:yU5g2KM7:TR?= MYnEUXNQ M4HPVGlEPTB;Mj62JO69VQ>? NWP4Z5hqOTZzOEW4OlU>
cells from the thymus of normal BALB/c mice NU\pdo5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGe3dIsyOCCwTR?= M1XMWlczKGh? NWf3U3diTE2VTx?= NFjYTZhKdmirYnn0d{BtgW2yaH;wdo9tcW[ncnH0bY9vKCiOQV[pJJdqfGhiSVO1NEBw\iB|IH7N Mlz1NVAxOjF7NEi=
MRK-nu-1 NV73eZk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwOES1JJBO NX:wW5JRW0GQR1XS
OCUB-M MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moj3TWM2OD13LkK0JJBO M2TDbXNCVkeHUh?=
SF539 MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fFSWlEPTB;MUGuOkBxVQ>? MkjCV2FPT0WU
ES4 NVrMT2hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnGzTWM2OD1{MT61JJBO MWjTRW5ITVJ?
RL95-2 NFrHSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTFyNzDwUS=> NYH2ZY9uW0GQR1XS
LC-2-ad MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDwWIhKUUN3ME20NlMheE1? MY\TRW5ITVJ?
Daudi NHz4SZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTzTWM2OD12M{SgdG0> MmTwV2FPT0WU
NTERA-S-cl-D1 M3LqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTR2MzDwUS=> NVm5O2NvW0GQR1XS
OS-RC-2 NUTRVIFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXWcXg2UUN3ME22OVIheE1? M4LOfHNCVkeHUh?=
VA-ES-BJ MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXmxNWM2UUN3ME23NlMheE1? NULhSnNNW0GQR1XS
GR-ST M{HTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HLZmlEPTB;OES2JJBO Mn3zV2FPT0WU
SW872 M{WwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPXeHpDUUN3ME24OFYheE1? NUPmbFA1W0GQR1XS
NOS-1 MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTh5MTDwUS=> NXTsV3Z3W0GQR1XS
MC116 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj6NHlKSzVyPUm4OUBxVQ>? M1zLNXNCVkeHUh?=
NCI-H1355 NXe1cWZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHKfod7UUN3ME2xMlAyKG6P MlK4V2FPT0WU
RPMI-8226 NVvhPFViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zBUWlEPTB;MT6xPUBvVQ>? NXXuVpAyW0GQR1XS
TE-15 NWHLfZBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS3cGxKSzVyPUGuN|Yhdk1? M3KwOnNCVkeHUh?=
Ramos-2G6-4C10 NF7CXWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHnbYVXUUN3ME2xMlQ3KG6P MUXTRW5ITVJ?
KU812 NVPmfm9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWftXIVPUUN3ME2yMlAyKG6P MmfHV2FPT0WU
EW-1 MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\YOlZoUUN3ME2yMlE4KG6P MYfTRW5ITVJ?
KS-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vifmlEPTB;Mj60OUBvVQ>? NFjTSWxUSU6JRWK=
SK-LMS-1 NYfCXJdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTCU241UUN3ME2yMlQ6KG6P MXLTRW5ITVJ?
TGBC1TKB Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJwNkmgcm0> NGTZVZVUSU6JRWK=
TE-6 MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFf4cplKSzVyPUKuO|chdk1? M3y4T3NCVkeHUh?=
ETK-1 NI\idoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJwOEKgcm0> M1rXVHNCVkeHUh?=
BE-13 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTJwOUmgcm0> M2XUcXNCVkeHUh?=
A3-KAW M2jWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDWb4NQUUN3ME2yMlk6KG6P NGe2RnBUSU6JRWK=
TE-10 NFnnOphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;wRYtKSzVyPUOuN{BvVQ>? NXK5UFl2W0GQR1XS
DOHH-2 NIXXUWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Lh[mlEPTB;Mz6zOUBvVQ>? NITScmdUSU6JRWK=
ES6 M1HyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn2wTWM2OD1|LkSzJI5O MULTRW5ITVJ?
OPM-2 NF7QVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTRwMUWgcm0> MX;TRW5ITVJ?
SH-4 MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkS0TWM2OD12LkO0JI5O Ml\5V2FPT0WU
NB13 M1Pnb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfX[pY5UUN3ME20MlM3KG6P M3\Cd3NCVkeHUh?=
HUTU-80 NX33[3BUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTRwNEKgcm0> M4DrWnNCVkeHUh?=
CCRF-CEM MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFmzbGlKSzVyPUSuPVQhdk1? NIXIPJpUSU6JRWK=
TGBC24TKB MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T1PWlEPTB;NT61NUBvVQ>? MljXV2FPT0WU
697 MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnFTWM2OD14LkK4JI5O MXTTRW5ITVJ?
J-RT3-T3-5 NWXZSlFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvWSXM5UUN3ME22MlQ3KG6P M{K5NHNCVkeHUh?=
KALS-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr0TWM2OD14LkW2JI5O NYfLeG1{W0GQR1XS
no-10 MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DNPWlEPTB;Nz6yPUBvVQ>? MkfGV2FPT0WU
SK-NEP-1 NWrY[XJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{m2cGlEPTB;OD63PUBvVQ>? MoDRV2FPT0WU
L-540 NHv0N|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV30ZZBxUUN3ME2xNE41OiCwTR?= NU[2OGE2W0GQR1XS
JiyoyeP-2003 NXPnUG5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXDXodiUUN3ME2xNE46PCCwTR?= NFvVPGhUSU6JRWK=
HH Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTVVGptUUN3ME2xNU4{QSCwTR?= NHf3ZppUSU6JRWK=
SR NUXRV2dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHOfnZVUUN3ME2xNU41PSCwTR?= MkS5V2FPT0WU
QIMR-WIL NICzSJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTFzLki1JI5O NFLiTFRUSU6JRWK=
A4-Fuk NF3IeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\DN2lEPTB;MUOuNVIhdk1? MVPTRW5ITVJ?
CESS NEnpcGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF|LkGzJI5O Mme4V2FPT0WU
KE-37 M1iyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fBdGlEPTB;MU[uNFchdk1? MVTTRW5ITVJ?
SK-UT-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWm4fWJ{UUN3ME2xOk45OSCwTR?= NVT0c5ZtW0GQR1XS
SIG-M5 M1TucGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL0enJKSzVyPUG3MlI2KG6P NHLKWFhUSU6JRWK=
HT MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTF5Lk[gcm0> NWHhc4JOW0GQR1XS
DEL NHyyN4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH5cGVmUUN3ME2xO{46QSCwTR?= NU\NPFJ3W0GQR1XS
SK-PN-DW MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJyLkKzJI5O NEjW[|VUSU6JRWK=
RPMI-8402 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvPc|NKSzVyPUKxMlc4KG6P MXjTRW5ITVJ?
RPMI-6666 NXHCUnRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTJ2LkSyJI5O NHix[nFUSU6JRWK=
NCI-H720 NEHDfG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTLTWM2OD1{NT60NUBvVQ>? MULTRW5ITVJ?
EW-16 MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi4O|JIUUN3ME2yOk45PyCwTR?= MXLTRW5ITVJ?
BL-70 NX7HR3N7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJ6LkO4JI5O MVXTRW5ITVJ?
SF126 NVLvUWhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml20TWM2OD1|MD6zPEBvVQ>? NWXB[2xMW0GQR1XS
BC-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTNzLkK2JI5O Ml[xV2FPT0WU
MHH-PREB-1 MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LJZWlEPTB;M{KuOFQhdk1? MoDwV2FPT0WU
A101D NELqO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i1cWlEPTB;M{KuOlIhdk1? NHPlN2JUSU6JRWK=
NMC-G1 NWDXOGRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXp[JZKSzVyPUOzMlY4KG6P NW\kOZpmW0GQR1XS
LB1047-RCC NGfsWmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\vUmlEPTB;M{SuOlkhdk1? NHTHO|FUSU6JRWK=
EM-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TyTWlEPTB;M{iuOVMhdk1? NGfsfWVUSU6JRWK=
COLO-684 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DVW2lEPTB;M{muPEBvVQ>? M3jWeHNCVkeHUh?=
Becker NGDkb2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTRzLkC1JI5O MXfTRW5ITVJ?
BL-41 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnySVR7UUN3ME20N{43PiCwTR?= NHTNSGlUSU6JRWK=
MDA-MB-134-VI NEjKbldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXsWm9VUUN3ME20OE4xOiCwTR?= MlvUV2FPT0WU
L-363 M2\sSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTR2LkezJI5O NGCwTpJUSU6JRWK=
ECC4 NX\wd5V{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvDOWVKSzVyPUS0Mlc5KG6P MmrmV2FPT0WU
A388 MlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTR2LkiyJI5O NY\GSG5OW0GQR1XS
HEL NWjKb3pFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHkTpNKSzVyPUS5Mlc6KG6P MlHXV2FPT0WU
RKO M1\lc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLJNJlmUUN3ME21NE4zQSCwTR?= MkWxV2FPT0WU
KINGS-1 NGfqS4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIC4flFKSzVyPUWxMlU2KG6P MkixV2FPT0WU
EB-3 M{TX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHTW|k4UUN3ME21Nk43PyCwTR?= NUnON4J5W0GQR1XS
ARH-77 NWLiV|JsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTV{Lkigcm0> M{P5PHNCVkeHUh?=
GCIY NHn5dopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;ROmlEPTB;NUOuOFYhdk1? Mo\SV2FPT0WU
NCI-H1304 M4fBUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvVUWdLUUN3ME21O{4zOiCwTR?= MYrTRW5ITVJ?
KARPAS-299 MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjVR3ZJUUN3ME22NU45OiCwTR?= NXLCelZPW0GQR1XS
IA-LM MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTWTWM2OD14OD6xN{BvVQ>? M1ntSXNCVkeHUh?=
GI-1 MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTdyLkO5JI5O NELiXWpUSU6JRWK=
TE-11 MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTd5LkG3JI5O NIDK[FZUSU6JRWK=
LS-411N NG[wcG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXyW|FKSzVyPUe3MlU4KG6P MULTRW5ITVJ?
no-11 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjnZmpKSzVyPUizMlI1KG6P NGjMOYVUSU6JRWK=
MV-4-11 M{j1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LDcGlEPTB;OEOuO|Mhdk1? NWDCbHh2W0GQR1XS
BV-173 NGq4eItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDNTW5KSzVyPUizMlk4KG6P NFLoOW5USU6JRWK=
CMK MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXOxUGlnUUN3ME24OE4yPiCwTR?= Ml;SV2FPT0WU
LC4-1 NFPWUZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYWzd2tvUUN3ME24Ok44OiCwTR?= M13odHNCVkeHUh?=
COR-L279 M{nqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33qfWlEPTB;OEeuNlUhdk1? MYPTRW5ITVJ?
NCI-H209 NYH3d214T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrQSJhKSzVyPUi3MlQyKG6P NEfZNnZUSU6JRWK=
Raji NGjVPJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzvTWM2OD16OT63NkBvVQ>? M2TncXNCVkeHUh?=
LB996-RCC NH;XdZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{m3UmlEPTB;OUOuOFMhdk1? M2Da[HNCVkeHUh?=
NCI-H526 NVj1UVcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTl|LkW5JI5O MVXTRW5ITVJ?
KGN NIrLZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTl4LkK5JI5O NXPwVllpW0GQR1XS
MOLT-4 M{TLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\UW2lEPTB;OU[uO|khdk1? NXfPcmhiW0GQR1XS
PF-382 NWf5T4VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTl4Lke5JI5O M3jveHNCVkeHUh?=
BC-3 NETLfJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NViyR|N7UUN3ME25PU4yQCCwTR?= NImwZYZUSU6JRWK=
KARPAS-422 NWTqcFloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTFyMj6wPUBvVQ>? M3P5XHNCVkeHUh?=
SBC-1 NU\GcppqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Oz[2lEPTB;MUC3Mlc2KG6P MUXTRW5ITVJ?
LC-1F MlrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPuW|JCUUN3ME2xNFgvODVibl2= MX7TRW5ITVJ?
GB-1 M3rmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFyOT6wNkBvVQ>? MYXTRW5ITVJ?
SNB75 NGf4SGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTFzOT62PUBvVQ>? MnHsV2FPT0WU
BB65-RCC M4Hw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnhVplKSzVyPUGxPU46OyCwTR?= M3LnWHNCVkeHUh?=
NCI-N87 NH3pUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTF{MT65PEBvVQ>? NEDnXmRUSU6JRWK=
IST-MEL1 NYD4T2ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP2UGNXUUN3ME2xNlIvOzhibl2= MX3TRW5ITVJ?
HOP-62 M4rDTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTvfpA2UUN3ME2xNlYvQDlibl2= NXHTbo52W0GQR1XS
ACN M4TJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWm5Z3N1UUN3ME2xOFYvPzVibl2= MkC1V2FPT0WU
DMS-114 MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknHTWM2OD1zNUCuOlchdk1? NYHUVWMyW0GQR1XS
MLMA M4LJOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHjO2hiUUN3ME2xOVkvQDhibl2= M3XzTnNCVkeHUh?=
HT-144 MmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjKZVhKSzVyPUG2OU41OyCwTR?= NHfI[GVUSU6JRWK=
C2BBe1 Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDYTWM2OD1zNkeuO|Yhdk1? M1uzXnNCVkeHUh?=
L-428 NXPM[XA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVi4b2d1UUN3ME2xO|cvPyCwTR?= MVTTRW5ITVJ?
DU-4475 M{Hw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXqbodYUUN3ME2xPFcvPjhibl2= NY\6UlFuW0GQR1XS
CP67-MEL NWf5e3VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\YNGJrUUN3ME2xPVkvOzhibl2= NIGyfpJUSU6JRWK=
MEG-01 Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDafVNHUUN3ME2yNFEvQTZibl2= NVr4RpprW0GQR1XS
IST-SL2 NVfiVY5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPNb2hKSzVyPUKwPE43OyCwTR?= MVnTRW5ITVJ?
ES8 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3SOZNKSzVyPUKyOU46PCCwTR?= MljTV2FPT0WU
COLO-800 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3SXHNvUUN3ME2yN|UvOjhibl2= NVXadllFW0GQR1XS
MFH-ino M{TQcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjaTWM2OD1{M{WuPFQhdk1? MX3TRW5ITVJ?
OVCAR-4 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDYZm5FUUN3ME2yN|cvOjRibl2= NWnwS3RmW0GQR1XS
PSN1 MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPrfVdNUUN3ME2yOFIvPzFibl2= M4XNUnNCVkeHUh?=
EW-12 M4Hr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvqTWM2OD1{NEOuNUBvVQ>? NF\hZ49USU6JRWK=
HCC1599 MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJ4MT60O{BvVQ>? MWXTRW5ITVJ?
SJSA-1 MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jFVWlEPTB;MkexMlQ3KG6P M1PzUHNCVkeHUh?=
ST486 NV7MUIk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELBSGxKSzVyPUK5Ok4yPCCwTR?= NXTIXVkzW0GQR1XS
NOMO-1 NHfBdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Xk[2lEPTB;M{CwMlIyKG6P MXzTRW5ITVJ?
MN-60 NYLZNoh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PzfGlEPTB;M{C1MlMzKG6P M4XwWHNCVkeHUh?=
HCC1187 NX7UPYhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLITWM2OD1|MEeuNlUhdk1? MUTTRW5ITVJ?
SW982 MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\pPGlEPTB;M{G0Mlc2KG6P NYW0XWc5W0GQR1XS
LB647-SCLC NEjVTWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[0TWM2OD1|MkiuO|Ehdk1? M3njfHNCVkeHUh?=
HC-1 MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfIWmdKSzVyPUOzOU42KG6P MmXsV2FPT0WU
EHEB M4X4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\4TWM2OD1|M{euOVIhdk1? M2iyT3NCVkeHUh?=
TUR M4TCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTN4Mz65OUBvVQ>? MUjTRW5ITVJ?
LU-139 NGXlc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTN5OD6wNkBvVQ>? MUPTRW5ITVJ?
NB1 M1vzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTN6ND60OUBvVQ>? NWTW[mdlW0GQR1XS
BB30-HNC NV\oR2dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTN6OD6zNkBvVQ>? NHf5SpNUSU6JRWK=
HAL-01 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTN6OT6yOkBvVQ>? MmXmV2FPT0WU
K5 NFyw[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDjTWM2OD12MUGuN|chdk1? NWXKT3l5W0GQR1XS
MZ2-MEL Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjNTWM2OD12MUOuOlQhdk1? NFzUd2VUSU6JRWK=
RXF393 Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTwTWM2OD12MU[uOFUhdk1? NFvNVFdUSU6JRWK=
NCI-H1648 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LxUWlEPTB;NEG3MlU{KG6P MmOzV2FPT0WU
TE-12 NFXpfHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO2emNKSzVyPUSzOE4zPiCwTR?= MkniV2FPT0WU
EoL-1- NHr5bZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYmzN5RHUUN3ME20N|cvQThibl2= NFXneVFUSU6JRWK=
JAR M3e5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jtWGlEPTB;NEO4MlYzKG6P MUfTRW5ITVJ?
DSH1 NXLjZVVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\tO5ZKSzVyPUS1PE46OSCwTR?= NHr1VZRUSU6JRWK=
NCI-H187 NE\w[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXZdotDUUN3ME20OlIvQDFibl2= MlezV2FPT0WU
HCE-4 NHLRTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mln3TWM2OD12N{euOlYhdk1? M{LLb3NCVkeHUh?=
8-MG-BA NWXXNXhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3W4TWlEPTB;NUixMlUzKG6P MYLTRW5ITVJ?
KLE NX3QenJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;jTWM2OD13OEWuNkBvVQ>? NGPxO2hUSU6JRWK=
KNS-42 NVvSeW9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP2S3FKSzVyPUW4Ok45OSCwTR?= M2T4fXNCVkeHUh?=
MSTO-211H MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPiRodKSzVyPU[wPU44PCCwTR?= M3LYRXNCVkeHUh?=
GDM-1 M4GxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[ybmlEPTB;NkG0MlA6KG6P NEDUdZhUSU6JRWK=
TE-1 M1PlZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfQTWM2OD14NE[uNVIhdk1? NFHQ[mpUSU6JRWK=
BT-474 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:wTWM2OD14NEeuNFYhdk1? NGrTfGpUSU6JRWK=
KARPAS-45 NEXsUG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHRTWM2OD14NEeuOkBvVQ>? M3fP[XNCVkeHUh?=
MOLT-16 Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVmzZYlIUUN3ME22OFcvQTNibl2= NV\scFJ7W0GQR1XS
KURAMOCHI M4rNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mme4TWM2OD14NUeuOVEhdk1? MnrVV2FPT0WU
K-562 NXXQOZNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTZ4OT61NUBvVQ>? M2TjNXNCVkeHUh?=
EKVX MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L3cmlEPTB;NkeyMlcyKG6P MkfsV2FPT0WU
GAK NIPRTHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXUTWM2OD14N{WuN{BvVQ>? M2fIdnNCVkeHUh?=
NCI-SNU-5 NHnGXJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvITWM2OD14OUCuNFEhdk1? MVPTRW5ITVJ?
NCI-H2126 NIfhXYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofKTWM2OD15Mk[uPFchdk1? NVXUblNmW0GQR1XS
CTV-1 M4LoVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTydoJHUUN3ME23OFQvQSCwTR?= M4Tw[3NCVkeHUh?=
SW962 NVn6c|ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTd2OD60OEBvVQ>? MUfTRW5ITVJ?
MONO-MAC-6 MlTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHm5Z2RKSzVyPUe1Ok46OyCwTR?= MlrYV2FPT0WU
NCI-H748 MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17EXWlEPTB;N{W4Mlk6KG6P NEHxbVRUSU6JRWK=
NCI-H524 NUnzN5RMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlS5TWM2OD15OECuO|Mhdk1? NV31cpF5W0GQR1XS
LS-123 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrkbmxKSzVyPUe5OU43QSCwTR?= NXn2NWpyW0GQR1XS
NB7 NGLpV|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\FbY9VUUN3ME24NVQvOTRibl2= NXXzbohEW0GQR1XS
LS-1034 M1K1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M172cWlEPTB;OEK4Mlk5KG6P NFjGcnNUSU6JRWK=
TE-5 NHTCZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLUPXZpUUN3ME24PFMvPTZibl2= NIPyTWNUSU6JRWK=
A704 NFzsdmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTh7OT6xOUBvVQ>? M4Hr[3NCVkeHUh?=
TK10 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nZdGlEPTB;OUG2MlA{KG6P M{DTcHNCVkeHUh?=
NCI-H345 M4\3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HMUGlEPTB;OUSzMlIzKG6P NVjL[2NFW0GQR1XS
CGTH-W-1 MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTl2OD6xN{BvVQ>? MYrTRW5ITVJ?
NCI-H510A NWj5O3dIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXXSVdKSzVyPUm4OU4yOiCwTR?= MUTTRW5ITVJ?
NCI-H1963 NYrwSZRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK0TWM2OD1zLkCzNlkzKM7:TR?= M2\OOnNCVkeHUh?=
SCC-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfoZ4NXUUN3ME2xMlA{PDF2IN88US=> MorZV2FPT0WU
EW-11 NEjv[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFwMEi3OFMh|ryP MV;TRW5ITVJ?
CPC-N MkPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f0[GlEPTB;MT6wPFgh|ryP MkLKV2FPT0WU
NCI-H1417 Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFwMUKyOkDPxE1? M4HxcnNCVkeHUh?=
DG-75 NWLsXXJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkj6TWM2OD1zLkG2Nlg2KM7:TR?= MVvTRW5ITVJ?
HD-MY-Z MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\nOVBLUUN3ME2xMlE3PDF4IN88US=> M3LBWXNCVkeHUh?=
ATN-1 NVzDUpV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkizTWM2OD1zLkK2NlA6KM7:TR?= NGnINXNUSU6JRWK=
KM-H2 MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzwZphbUUN3ME2xMlI3PDB6IN88US=> MnfvV2FPT0WU
NCI-H2081 NVrVdWdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFwMk[2N|ch|ryP MVnTRW5ITVJ?
HL-60 M4\jVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEW1bpVKSzVyPUGuNlY6PTlizszN NYTTVnVXW0GQR1XS
DB MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTFwMkeyOFIh|ryP MXLTRW5ITVJ?
NCI-H1522 M4HaO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPpcGhKSzVyPUGuNlg5QDdizszN NIDK[YNUSU6JRWK=
AM-38 M2XkdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3oTWM2OD1zLkOwO|Ih|ryP NGCxT3dUSU6JRWK=
NCI-H446 NHrpWlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjMTGJKSzVyPUGuN|IyOjFizszN Ml;oV2FPT0WU
SU-DHL-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f4TWlEPTB;MT6zNlgxOSEQvF2= NYfXRZFZW0GQR1XS
NH-12 M{HGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jpbWlEPTB;MT6zOlM4PCEQvF2= NYXIfHJ[W0GQR1XS
DMS-79 NHTseYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;yZWlEPTB;MT6zOlg3PiEQvF2= MmHmV2FPT0WU
NCI-H716 NI\iSpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\M[WlEPTB;MT6zPFk5PiEQvF2= M3T0[3NCVkeHUh?=
ML-2 M4rOeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrwXHlKSzVyPUGuOFE2OjlizszN M{jod3NCVkeHUh?=
NB10 NWjpZVROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGP2SYJKSzVyPUGuOFY3OzJizszN NIGwWJFUSU6JRWK=
ONS-76 MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPrTWM2OD1zLkWzOVY6KM7:TR?= M1vUTHNCVkeHUh?=
LOUCY MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL6RWpKSzVyPUGuOVQ3PTdizszN M{jOVXNCVkeHUh?=
SCLC-21H MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nR[WlEPTB;MT61PFU5OiEQvF2= MYTTRW5ITVJ?
TGW Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\TTWM2OD1zLk[zPVc2KM7:TR?= NGHxN3FUSU6JRWK=
LXF-289 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFwN{OyOlgh|ryP NWnmW2dzW0GQR1XS
BB49-HNC MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzYZYFtUUN3ME2xMlc{PTh4IN88US=> MYTTRW5ITVJ?
NCI-H747 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfETWM2OD1zLke1N|Q3KM7:TR?= NE\LfGhUSU6JRWK=
LU-165 NHLne4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDDTWM2OD1zLki0PVg3KM7:TR?= M1rEeXNCVkeHUh?=
OMC-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XncmlEPTB;MT65OVA3PiEQvF2= MlLtV2FPT0WU
RCC10RGB MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1viXGlEPTB;MT65OVgyPyEQvF2= NV7idnBvW0GQR1XS
SW684 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXJTWM2OD1zLkm2NFk6KM7:TR?= NHOxUZFUSU6JRWK=
TE-8 NV3EU3BoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJwMEW1OVkh|ryP M{KyenNCVkeHUh?=
SK-N-DZ MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\mXWlEPTB;Mj6xN|I4PCEQvF2= NITGZZFUSU6JRWK=
EVSA-T MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rMWmlEPTB;Mj6xO|MyPSEQvF2= NWTWZYprW0GQR1XS
KASUMI-1 MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmqyTWM2OD1{LkG4PFE2KM7:TR?= MmH1V2FPT0WU
NKM-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJwMkW0O|Ih|ryP M4roO3NCVkeHUh?=
CAL-148 M3jNUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfsOXFKSzVyPUKuN|M3OTRizszN MWTTRW5ITVJ?
NCI-H64 MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTN[3JtUUN3ME2yMlM1OjN{IN88US=> MVTTRW5ITVJ?
KNS-81-FD M4i1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDSPVhKSzVyPUKuN|Y3OiEQvF2= NYG1RlA4W0GQR1XS
KM12 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2CzSGlEPTB;Mj60NFg{QSEQvF2= NEPrcJlUSU6JRWK=
SW954 NHHtTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX2blFKSzVyPUKuOFc4PzlizszN MXvTRW5ITVJ?
NCI-H1395 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXH[496UUN3ME2yMlUzPjR3IN88US=> MWTTRW5ITVJ?
DJM-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWThN2puUUN3ME2yMlYxPjNizszN MVjTRW5ITVJ?
COLO-668 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJwOEK2PVUh|ryP MlrVV2FPT0WU
NCI-H1436 NGT5SoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[ydYlKSzVyPUKuPFU3OTVizszN M{e4TXNCVkeHUh?=
LB2241-RCC NF73fXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HCSGlEPTB;Mj64Olg{QSEQvF2= M1fzenNCVkeHUh?=
GT3TKB NXrke5VGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnOTWM2OD1{Lki5NFU2KM7:TR?= NXjBV5R6W0GQR1XS
COLO-824 MkC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\Nd2lEPTB;Mj64PVc3QCEQvF2= NE\ONYlUSU6JRWK=
ES1 M2PET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjVWnNKSzVyPUKuPFk5PzlizszN NXizW211W0GQR1XS
LB771-HNC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PMO2lEPTB;Mj65NFk1PiEQvF2= MYDTRW5ITVJ?
GI-ME-N NYL6THV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELYVHBKSzVyPUOuNFA6ODRizszN MVfTRW5ITVJ?
NALM-6 NF7EbpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnSVVViUUN3ME2zMlAxQTN|IN88US=> MornV2FPT0WU
LU-134-A NHPjVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LlcGlEPTB;Mz6wOVQzPSEQvF2= MlL5V2FPT0WU
DMS-153 NGT2TINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj3RWpKSzVyPUOuNFU5OjRizszN MlPjV2FPT0WU
MZ1-PC M2H3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfPOIVNUUN3ME2zMlA6ODd6IN88US=> MoTHV2FPT0WU
NCI-H1155 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Xs[2lEPTB;Mz6xNVYyKM7:TR?= MkW0V2FPT0WU
CAS-1 NHf4R3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4SzSGlEPTB;Mz6xN|cxPyEQvF2= NGT4WHZUSU6JRWK=
D-502MG M2HLZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTNwMUSzPUDPxE1? MX\TRW5ITVJ?
NCI-H2141 M3nqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PJemlEPTB;Mz6xO|Q2OiEQvF2= MYPTRW5ITVJ?
NB6 NXvVTXpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTNwMUiyOVkh|ryP NEjDPVNUSU6JRWK=
NCCIT NVG5cWZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLXTWM2OD1|LkKxPFA6KM7:TR?= NYTveVhqW0GQR1XS
NB69 NXvxdnhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2facWlEPTB;Mz6zNVg6OSEQvF2= NH7mc2FUSU6JRWK=
JVM-2 Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTNwM{[0N|Mh|ryP NVfPPIZHW0GQR1XS
K052 NWH1Wo5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHSxOoFKSzVyPUOuN|c6PjhizszN NVK1dZZXW0GQR1XS
HCC2157 NWrnd5U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTNwNUOyNlgh|ryP NV7SPGV1W0GQR1XS
KMOE-2 NGHBfItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjBcYtKSzVyPUOuOVQzPDJizszN NYjK[4o5W0GQR1XS
SF268 M3fCNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXDVINKSzVyPUOuO|E2PTRizszN NFXkdnFUSU6JRWK=
CHP-126 M3POe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDwNJVWUUN3ME2zMlc3PDV6IN88US=> NX3YdHBKW0GQR1XS
CP66-MEL M4W4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmK2TWM2OD1|Lke5NFk1KM7:TR?= MUfTRW5ITVJ?
NCI-H69 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTRwMEG5N|Yh|ryP NUjtXJhSW0GQR1XS
A253 MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fIemlEPTB;ND6wNlExOSEQvF2= MUPTRW5ITVJ?
NB14 NGXoWFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3ZOHVKSzVyPUSuNVA1PzlizszN MWXTRW5ITVJ?
NCI-H1694 M2\NSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nXO2lEPTB;ND6xN|EyOiEQvF2= Mn\VV2FPT0WU
NCI-H2196 NXnIVmFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLCc4FCUUN3ME20MlE4OTZ7IN88US=> M{fYU3NCVkeHUh?=
TE-9 NHLTV4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe4N3ZKSzVyPUSuNVc2QDJizszN M{fwSXNCVkeHUh?=
D-283MED MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j6T2lEPTB;ND6xPFg1KM7:TR?= NFm1TJVUSU6JRWK=
OCI-AML2 MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;zUZZKSzVyPUSuNVk1QDlizszN Mnn3V2FPT0WU
D-263MG MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[2PHVKSzVyPUSuNlI6PjFizszN Mnz5V2FPT0WU
MPP-89 M1TTOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPKSXZQUUN3ME20MlI4OzB2IN88US=> NFHNclJUSU6JRWK=
LAMA-84 Mnf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkCxTWM2OD12LkOwOFIyKM7:TR?= MoL5V2FPT0WU
LB373-MEL-D MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmn0TWM2OD12LkO2O|g6KM7:TR?= MmrjV2FPT0WU
UACC-257 NVfvVHFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH64R3JKSzVyPUSuN|k2OzRizszN Moq1V2FPT0WU
MC-CAR M4WycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTRwNEO5PUDPxE1? MU\TRW5ITVJ?
COLO-320-HSR MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTLTWM2OD12LkS0OFI4KM7:TR?= NVz4dGtHW0GQR1XS
P30-OHK M{DmdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGSwcnJKSzVyPUSuOlY2QDFizszN NELUe|ZUSU6JRWK=
UACC-812 NUnFS2VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[zdYp{UUN3ME20MlY6OTZzIN88US=> MXrTRW5ITVJ?
CTB-1 NIHL[HhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:2cll4UUN3ME20MlcyPTV3IN88US=> MlHCV2FPT0WU
ALL-PO MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFiy[HdKSzVyPUSuPFQxPzdizszN NHfO[JVUSU6JRWK=
SK-MEL-2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTQTWM2OD12Lki2PVU2KM7:TR?= NWOybnVkW0GQR1XS
TC-YIK Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr5T21KSzVyPUSuPVc6PDJizszN NYfpXWxxW0GQR1XS
NCI-H1882 M3TpU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLxfFM4UUN3ME21MlAzODBzIN88US=> MWfTRW5ITVJ?
MHH-CALL-2 M4XrUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjReVhKSzVyPUWuNFUxPDJizszN MXrTRW5ITVJ?
U-87-MG NWfWO4lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ezc2lEPTB;NT6wPVQ3PiEQvF2= M4SzVnNCVkeHUh?=
NCI-H1092 MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzUTG85UUN3ME21MlI3PTV3IN88US=> NVX5OIRsW0GQR1XS
TE-441-T NIPhUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DMNWlEPTB;NT6yO|gzKM7:TR?= NHH4b2JUSU6JRWK=
SK-MEL-1 NFKweXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTVwMkmwOFQh|ryP MXrTRW5ITVJ?
EW-22 NX;nNZRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXITWM2OD13LkK5OFY3KM7:TR?= NW\yTXF1W0GQR1XS
MZ7-mel MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLvbHdKSzVyPUWuOFA3QTFizszN MVrTRW5ITVJ?
LP-1 MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlmyTWM2OD13LkSxNlkyKM7:TR?= MVzTRW5ITVJ?
NCI-SNU-16 M{jIb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTVwNkSwO|Qh|ryP M2LTfHNCVkeHUh?=
LU-65 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zjfGlEPTB;NT63OlM4OyEQvF2= MVTTRW5ITVJ?
CW-2 MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7w[ZJVUUN3ME21Mlg2QTV7IN88US=> M3TwPHNCVkeHUh?=
WSU-NHL MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\neJhKSzVyPUWuPVUyPzRizszN MXHTRW5ITVJ?
IST-MES1 MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIm4[WJKSzVyPUWuPVU1PDNizszN MmfMV2FPT0WU
U-266 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTVwOUiyNFIh|ryP NFK2V3dUSU6JRWK=
TALL-1 NVrPT2lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MniwTWM2OD14LkG0Olg5KM7:TR?= MUPTRW5ITVJ?
Calu-6 MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTZwMUWzNVYh|ryP M1ntO3NCVkeHUh?=
MMAC-SF MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTZwMUi1OVYh|ryP MV\TRW5ITVJ?
NCI-H82 NWXKUWptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33wRmlEPTB;Nj6yNFQ5QSEQvF2= NHLTbnZUSU6JRWK=
RS4-11 MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfYSG5KSzVyPU[uNlU5QTdizszN NFLxcGZUSU6JRWK=
SNU-C2B NFHqN|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;nUGlEPTB;Nj60NFk3QSEQvF2= MnXwV2FPT0WU
BOKU M{W1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13xPGlEPTB;Nj60O|U6PyEQvF2= NX7ib|NHW0GQR1XS
C8166 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;FcVNrUUN3ME22MlU2QTF{IN88US=> MUfTRW5ITVJ?
D-247MG MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTdwMESzOFch|ryP MlrmV2FPT0WU
EW-18 Mmj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\FO3RvUUN3ME23MlA4Ojl{IN88US=> MWXTRW5ITVJ?
KG-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fnTmlEPTB;Nz62Nlc{QCEQvF2= M17qR3NCVkeHUh?=
REH M1TSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L2RWlEPTB;Nz62PFExQSEQvF2= NVXHW21zW0GQR1XS
U-698-M NEjKNFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHH3cmdKSzVyPUeuPFQ{OTVizszN MlXlV2FPT0WU
KP-N-RT-BM-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTdwOUOwNlkh|ryP MmXFV2FPT0WU
MS-1 Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLHPZd1UUN3ME23Mlk3ODRzIN88US=> M2\pWHNCVkeHUh?=
SNU-C1 NYTHO5JFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX2yRZI6UUN3ME23Mlk5OTl{IN88US=> MULTRW5ITVJ?
SK-MM-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjScmtKSzVyPUiuNlYxPjVizszN MlLnV2FPT0WU
LAN-6 MkTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3iPFlKSzVyPUiuN|AxODFizszN MoPRV2FPT0WU
NEC8 NGLveJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljRTWM2OD16LkOwOlkyKM7:TR?= M{nS[3NCVkeHUh?=
NCI-H1770 NGnxN|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvJSm1KSzVyPUiuN|gxODJizszN NXn3fpNXW0GQR1XS
D-336MG NYC5dmlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkm2TWM2OD16LkSwNVE3KM7:TR?= MUnTRW5ITVJ?
COLO-829 MmHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWn6NW5ZUUN3ME24MlQ5QDd7IN88US=> NW\CUWc1W0GQR1XS
LS-513 NXHmZ5hNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PJfWlEPTB;OD61PVU6QSEQvF2= NUfRVGlmW0GQR1XS
YT MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRThwNkK0Nlch|ryP M2f0ZnNCVkeHUh?=
EW-24 NFLMVJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHyyOHRKSzVyPUiuO|Y2PCEQvF2= M2fzbXNCVkeHUh?=
IST-SL1 NUTGTphrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrET41tUUN3ME24Mlg3PTR|IN88US=> NIDPNIZUSU6JRWK=
CA46 NHzrZ|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljCTWM2OD16Lkm1NFk5KM7:TR?= NHHuRmFUSU6JRWK=
NCI-H1838 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlexTWM2OD16Lkm4OlAzKM7:TR?= MWLTRW5ITVJ?
NCI-H719 MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTlwMkWyO|kh|ryP NGXxd3dUSU6JRWK=
HCE-T MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYiwc2ZxUUN3ME25MlMxQDVzIN88US=> NUDaV4N{W0GQR1XS
A498 NXzxdIE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTlwM{[xNlQh|ryP M4jRdXNCVkeHUh?=
LB831-BLC M2rYWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XlPGlEPTB;OT63OlUzOSEQvF2= NETa[YJUSU6JRWK=
SKM-1 M1vHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXT0d|BKUUN3ME25Mlg2QTZ|IN88US=> NXf2cFdtW0GQR1XS
THP-1 NWS1PVdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTWcXlKSzVyPUmuPVY6OThizszN NUXWPFJzW0GQR1XS
SHP-77 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFyLkSwO{DPxE1? NVSzcWJWW0GQR1XS
EW-3 NUfQb4xXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrafZlKSzVyPUGwMlYzQDlizszN NImwT|RUSU6JRWK=
KY821 NH74NFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr3W2FkUUN3ME2xNE44PjNizszN NYDiO41GW0GQR1XS
NCI-SNU-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7lelVCUUN3ME2xNU4xOjF5IN88US=> NIfaSmxUSU6JRWK=
HCC2218 NX7SV3JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFzLkO5PFYh|ryP NVWwTWJSW0GQR1XS
IM-9 NV\afpFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTFzLkWxNFYh|ryP NETLZ5VUSU6JRWK=
NCI-H889 MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X3R2lEPTB;MUGuOVMyOyEQvF2= MVrTRW5ITVJ?
HDLM-2 NYXGfYtKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTF{LkSxOVkh|ryP MmHpV2FPT0WU
LB2518-MEL MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYKxSFA1UUN3ME2xNk43QDF3IN88US=> MoHWV2FPT0WU
NCI-H23 M{HXNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zyVWlEPTB;MUOuNlQzPSEQvF2= MmLZV2FPT0WU
NB17 NGD3b4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LIc2lEPTB;MUOuOFU4QSEQvF2= NUXX[WZ7W0GQR1XS
NCI-H322M M{T1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF2LkSwOlgh|ryP M3zZO3NCVkeHUh?=
SUP-T1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT1bWtKSzVyPUG0MlQyOyEQvF2= M{LseXNCVkeHUh?=
ES3 MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vEZWlEPTB;MUWuNFcxOyEQvF2= MoD1V2FPT0WU
ES5 MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTF3LkC3PFch|ryP NVLo[mtyW0GQR1XS
NCI-H1650 M{[3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzmTWM2OD1zNT60PVc6KM7:TR?= NXTrS45NW0GQR1XS
NCI-H226 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvITWM2OD1zNT64O|Y5KM7:TR?= M3rkV3NCVkeHUh?=
COR-L88 M{DtUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTF4LkOxOEDPxE1? M4S4TXNCVkeHUh?=
SCC-15 NF;zVnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonQTWM2OD1zNj6zPFY6KM7:TR?= MWTTRW5ITVJ?
GOTO MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jkVWlEPTB;MU[uOFc6OyEQvF2= NFXJPIJUSU6JRWK=
SIMA NVXGZY9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTF4LkS4NFIh|ryP MnLOV2FPT0WU
NCI-H1299 NYfGSG85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXEOGdiUUN3ME2xO{4yPTlzIN88US=> NEe0S3lUSU6JRWK=
NCI-H1581 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\MfWdKSzVyPUG3MlQzOTlizszN M3rSeXNCVkeHUh?=
MHH-NB-11 NV7FT|VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfETWM2OD1zNz65Olg{KM7:TR?= M3TaOHNCVkeHUh?=
MFM-223 NGnvPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnvUnRKSzVyPUG4MlA2OzhizszN M1XFOnNCVkeHUh?=
ES7 M37UcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTF6LkW0N|Eh|ryP MVTTRW5ITVJ?
JVM-3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofmTWM2OD1zOD63NVch|ryP MWrTRW5ITVJ?
RL MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHRTWM2OD1{MD6zPFgh|ryP M3OxdHNCVkeHUh?=
EC-GI-10 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPtOGRRUUN3ME2yNU4zODRzIN88US=> M3WxNnNCVkeHUh?=
LNCaP-Clone-FGC NXnHSpRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTJzLk[3Olgh|ryP NHnlcnJUSU6JRWK=
IMR-5 M3S4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrQTWM2OD1{MT64OFk1KM7:TR?= NX3vdFNWW0GQR1XS
KP-N-YS MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJzLki3OUDPxE1? NHH2UVJUSU6JRWK=
Mo-T NE\kVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXqWYdKSzVyPUKyMlIyQDVizszN M{C0O3NCVkeHUh?=
NCI-H128 NGT5SmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\pbnplUUN3ME2yN{42QDV|IN88US=> MV3TRW5ITVJ?
RH-1 MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLmOWtjUUN3ME2yN{44QDZ4IN88US=> NETFNI1USU6JRWK=
NCI-H2171 MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJ2LkK0PFUh|ryP Mny2V2FPT0WU
RPMI-8866 MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFP4WWlKSzVyPUK2Mlc1OiEQvF2= NYjBRoptW0GQR1XS
SK-N-FI Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[1NZhKSzVyPUK3MlM5OTFizszN NF3KOpZUSU6JRWK=
LOXIMVI NFuye4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnNZllKSzVyPUK3MlgxPTFizszN MmjSV2FPT0WU
P31-FUJ MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTNzLkWzO|Qh|ryP NU\mOphwW0GQR1XS
KMS-12-PE MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TjZWlEPTB;NEmuOVMxOiEQvF2= MU\TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
臨床試験 A Phase II study of Rapamycin to erase angiofibromas in patients with Tuberous Sclerosis Complex (TSC) is currently ongoing.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

細胞アッセイ:

[3]

細胞株 U87-MG, T98G, and U373-MG
濃度 Dissolved in DMSO, final concentrations ~25 μM
反応時間 72 hours
実験の流れ

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

動物実験:

[7]

動物モデル Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
製剤 Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
投薬量 ~4 mg/kg/day
投与方法 Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Rapamycin (Sirolimus) SDF
分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管 3年-20℃
2年-80℃in solvent
別名 AY 22989,NSC-2260804
溶解度 (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

文献中の引用 (63)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related mTOR 阻害剤

  • MHY1485

    MHY1485は一種の有効的で、細胞浸透性 mTOR 活性剤で、オートファジー(autophagy)も有効に抑制します。

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021)は一種のGSK-3αとGSK-3β阻害剤で、IC50値が10 nM と6.7 nMに分かれます。

  • Dorsomorphin (Compound C, BML-275)

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183)は一種の有効的で、経口生物利用可能なAkt阻害剤で、Akt1、Akt2とAkt3に作用する時のKi値が0.08 nM、2 nMと2.6 nMそれぞれに分かれます。臨床2期。

  • Everolimus (RAD001)

    Everolimus (RAD001)は一種のmTOR阻害剤で、FKBP12に作用します。無細胞試験でIC50値は1.6-2.4 nMになります。

  • AZD8055

    AZD8055は一種の新たなATP競争性mTOR阻害剤で、MDA-MB-468細胞の中でIC50値は0.8 nMです。AZD8055はmTORに作用する選択性はPI3K亜型とATM/DNA-PKに作用する選択性より約1000倍が高くなります。臨床1期。

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin 1は一種の有効なmTORC1/2阻害剤で、無細胞試験でIC50値が2 nM/10 nMになって、mTORに作用する選択性はPI3Kに作用する選択性より1000倍が高くなります。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は一種の特定なmTOR阻害剤で、無細胞試験でIC50値は1.76 μMです。

  • INK 128 (MLN0128)

    INK 128 (MLN0128)は一種の有効的で、選択性mTOR阻害剤で、無細胞試験でこのIC50値が1 nMです。INK 128 (MLN0128)はmTORに作用する効果はI型PI3K亜型に作用する効果より200倍以上が高くなります。ラパマイシン(Rapamycin)に比べて、INK 128 (MLN0128)は優先にmTORC1/2を抑制し、促侵入遺伝子( pro-invasion genes )に敏感です。臨床1期。

最近チェックしたアイテム

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ